Home>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Tandutinib hydrochloride

Tandutinib hydrochloride Sale

(Synonyms: MLN518 hydrochloride; CT53518 hydrochloride) 目录号 : GC38853

An antagonist of PDGFRβ, FLT3, and c-Kit

Tandutinib hydrochloride Chemical Structure

Cas No.:2438900-70-8

规格 价格 库存 购买数量
Free Sample (0.1-0.5 mg) 待询 待询
10mM (in 1mL DMSO)
¥544.00
现货
50mg
¥495.00
现货
100mg
¥796.00
现货
200mg 待询 待询
500mg 待询 待询

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Tandutinib is a potent antagonist of platelet-derived growth factor receptor β (PDGFRβ), FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively).1 It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC50 = 3.4 ?M) and does not significantly inhibit other tyrosine or serine/threonine kinases.1,2 Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells.1,3 It also impairs the growth of colon cancer cells through its actions on the c-Kit receptor.4 Tandutinib reverses multidrug resistance in vitro by impairing the efflux activity of the multidrug resistance protein 7.5

1.Kelly, L.M., Yu, J.C., Boulton, C.L., et al.CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)Cancer Cell.1(5)421-432(2002) 2.Pandey, A., Volkots, D.L., Seroogy, J.M., et al.Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase familyJ. Med. Chem.45(17)3772-3793(2002) 3.Griswold, I.J., Shen, L.J., La Rosée, P., et al.Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesisBlood104(9)2912-2918(2004) 4.Ponnurangam, S., Standing, D., Rangarajan, P., et al.Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growthMol. Cancer Ther.12(5)598-609(2013) 5.Deng, W., Dai, C.L., Chen, J.J., et al.Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)Oncol. Rep.29(6)2479-2485(2013)

Chemical Properties

Cas No. 2438900-70-8 SDF
别名 MLN518 hydrochloride; CT53518 hydrochloride
Canonical SMILES O=C(N1CCN(C2=C(C(C=C3OCCCN4CCCCC4)=NC=N2)C=C3OC)CC1)NC5=CC=C(OC(C)C)C=C5.Cl
分子式 C31H43ClN6O4 分子量 599.16
溶解度 DMSO: ≥ 100 mg/mL (166.90 mM); Water: 100 mg/mL (166.90 mM) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.669 mL 8.345 mL 16.69 mL
5 mM 0.3338 mL 1.669 mL 3.338 mL
10 mM 0.1669 mL 0.8345 mL 1.669 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Gateways to clinical trials

Methods Find Exp Clin Pharmacol 2010 Jan-Feb;32(1):47-86.PMID:20383346doi

(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide, Alemtuzumab, Aliskiren fumarate, ALT-801, AN-2728, Anacetrapib, API, Aprepitant, ARQ-197, Ascorbic acid, Atazanavir sulfate, ATN-224, AVI-4658, Azacitidine, Azelnidipine; Belinostat, Bevacizumab, BI-2536, Biphasic insulin aspart, Bortezomib, Bovine lactoferrin, Bryostatin 1, Budesonide/formoterol fumarate; cAC10, Canfosfamide hydrochloride, Cediranib, Clofarabine, Cocaine conjugate vaccine; Darbepoetin alfa, Dasatinib, Denosumab, Disomotide, Doripenem, Dovitinib Lactate, Dronedarone hydrochloride, Drospirenone/estradiol, Dutasteride; Ecogramostim, Entinostat, Enzastaurin hydrochloride, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe, Ezetimibe/simvastatin; Fampridine, Fenretinide LXS, FFR-factor VIIa, Fingolimod hydrochloride, Frovatriptan; Gefitinib, Gimatecan, GP-2/GM-CSF; Iloperidone, Imatinib mesylate, Indibulin, Ipilimumab, Ivabradine hydrochloride; Lactobacillus rhamnosus, Lapatinib ditosylate, LC-07, Lenalidomide, Linifanib, Liposomal doxorubicin, Liposomal vincristine, Litenimod, Lutein; M-118, MDX-1401, MEDI-528, Midostaurin, Miglustat, MK-0657; Natalizumab, Nesiritide, NGR-TNF, Niacin/simvastatin; Obatoclax mesylate, Olaparib, Omacetaxine mepesuccinate; Paclitaxel nanoparticles, Paclitaxel-eluting stent, Palonosetron hydrochloride, Pazopanib hydrochloride, Pegfilgrastim, Pemetrexed disodium, PER.C-flu, Perifosine, PF-02341066, Pimecrolimus, Pitrakinra, Plerixafor hydrochloride, Posaconazole; Rasburicase, Recombinant human relaxin H2, ReoT3D, Retaspimycin hydrochloride, Riferminogene pecaplasmid, Rindopepimut, Romiplostim, Ronacaleret hydrochloride, Rosuvastatin calcium, Rotigotine; Sagopilone, sALP-FcD10, SAR-245409, SCH-697243, Selumetinib, Sirolimus-eluting stent, SIR-Spheres, Sitagliptin phosphate monohydrate, Sitaxentan sodium, Sorafenib, Sunitinib malate; Tadalafil, Tandutinib, Tasimelteon, Temsirolimus, Teriparatide, Tiotropium bromide, TIV, Trabectedin, Tremelimumab, TRU-016; Vadimezan, Val8-GLP-1(7-37)OH, Vandetanib, Vernakalant hydrochloride, Voreloxin, Voriconazole, Vorinostat, Yttrium 90 (90Y) ibritumomab tiuxetan; Zeaxanthin, Ziprasidone hydrochloride, Zosuquidar trihydrochloride.

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinib

Molecules 2006 Apr 10;11(4):286-97.PMID:17962760DOI:10.3390/11040286.

The synthesis of three substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib (1), erlotinib (2) and gefitinib (3) in improved yields is reported. The intermediates were characterized by NMR and the purities determined by HPLC.